Platelets News and Research

RSS

FDA allows CryoLife to begin PerClot clinical trial in the U.S.

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration.

2 Apr 2014

Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.

2 Apr 2014

Research uncovers link between diet and blood cell markers of heart attack associated inflammation

New research further illuminates the heart-healthy benefits of the Mediterranean diet, tying the eating plan to lower levels of platelets and white blood cells, two markers of inflammation. Inflammation has an association with greater risk of heart attack and stroke.

1 Apr 2014

Research pinpoints location of key genetic regulators in blood cells

Research published online today in Blood, the Journal of the American Society of Hematology, presents an unprecedented look at five unique blood cells in the human body, pinpointing the location of key genetic regulators in these cells and providing a new tool that may help scientists to identify how blood cells form and shed light on the etiology of blood diseases.

27 Mar 2014

Research findings may be beneficial for creation of purer HSC lines for clinical treatments

Hematopoietic stem cells are now routinely used to treat patients with cancers and other disorders of the blood and immune systems, but researchers knew little about the progenitor cells that give rise to them during embryonic development.

24 Mar 2014

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.

7 Mar 2014

Protamine antidote can be effective in reversing low-molecular-weight heparin

Low-molecular-weight heparin is commonly used in surgeries to prevent dangerous blood clots. But when patients experience the other extreme - uncontrolled bleeding - in response to low-molecular-weight heparin, there is no antidote.

4 Mar 2014

New optical device may help docs to diagnose blood coagulation status in near real time

Defective blood coagulation is one of the leading causes of preventable death in patients who have suffered trauma or undergone surgery. The body's natural defense against severe blood loss is the clotting process, in which platelets, plasma proteins, and other blood components interact to form a sticky, mesh-like structure.

26 Feb 2014

Researchers discover that immune cells control blood stem cells in bone marrow

Researchers in Bern have discovered that, during a viral infection, immune cells control the blood stem cells in the bone marrow and therefore also the body's own defences. The findings could allow for new forms of therapy, such as for bone marrow diseases like leukaemia.

24 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

The National Institutes of Health has awarded grants totaling $3 million for two nanoparticle research projects in which Penn State bioengineer Jian Yang is co-principal investigator.

19 Feb 2014

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby - twice as long as previously recognized, according to a large study presented at the American Stroke Association's International Stroke Conference 2014.

14 Feb 2014

Engineers turn cells common in scar tissue into colonies of beating heart cells

Poets and physicians know that a scarred heart cannot beat the way it used to, but the science of reprogramming cells offers hope--for the physical heart, at least.

13 Feb 2014

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

23 Jan 2014

Risk factor for life-threatening bowel infection in premature infants identified

Many premature infants suffer a life-threatening bowel infection called necrotizing enterocolitis (NEC).

17 Jan 2014

Researchers discover key step to stem bleeding, reduce obstruction in blood flow during clot formation

Red blood cells are the body's true shape shifters, perhaps the most malleable of all cell types, transforming - among many other forms -- into compressed discs capable of going through capillaries with diameters smaller than the blood cell itself.

10 Jan 2014

T2HemoStat detection of novel clot behavior could direct therapeutic choices for stroke, heart attack victims

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.

10 Jan 2014

NeoGenomics launches new test for detection of mutations in CALR gene

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology last month.

8 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014